TherapeuticsMD submits NDA for hormone therapy to treat vasomotor symptoms

TherapeuticsMD (NSDQ:TXMD) has submitted its bio-identical hormone therapy to the FDA for approval as a treatment for moderate-to-severe vasomotor symptoms due to menopause.

The company’s investigational combination of estradiol and progesterone is delivered in a single, oral soft-gel capsule.

Get the full story at our sister site, Drug Delivery Business News.

 

The post TherapeuticsMD submits NDA for hormone therapy to treat vasomotor symptoms appeared first on MassDevice.

from MassDevice http://ift.tt/2CkbjM9